LY294002 and rapamycin co-operate to inhibit T-cell proliferation

Area of Science:

• Immunology
• Cell Biology
• Molecular Biology

Background:

• T-cell proliferation is essential for adaptive immunity, regulated by T-cell receptor, co-stimulation, and cytokines like IL-2.
• Phosphatidylinositol 3-kinase (PI3K) is a key signaling molecule downstream of these pathways, regulating lymphocyte proliferation.

Purpose of the Study:

• To investigate the role of PI3K in regulating T-cell proliferation.
• To determine the molecular mechanisms by which PI3K controls cell cycle progression in T-cells.
• To evaluate the efficacy of combined PI3K and mTOR inhibition on T-cell proliferation.

Main Methods:

• Investigated the transcriptional and post-transcriptional regulation of cyclin D2 and cyclin D3 by PI3K in T-lymphoblasts.
• Utilized PI3K inhibitor LY294002 and mTOR inhibitor rapamycin to assess their effects on cyclin induction and T-cell proliferation.
• Examined the cooperative effects of LY294002 and rapamycin in various T-cell models, including IL-2 stimulated Kit225 cells and peripheral blood lymphocytes.

Main Results:

• PI3K inhibition by LY294002 prevented the induction of cyclin D-type mRNA and protein in T-lymphoblasts.
• Rapamycin inhibited the protein induction of cyclins D2 and D3, indicating a role for mTOR downstream of PI3K.
• Combined LY294002 and rapamycin demonstrated cooperative inhibition of T-cell proliferation across different stimulation conditions.

Conclusions:

• PI3K plays a critical role in regulating T-cell proliferation in response to diverse immune stimuli.
• The findings suggest that targeting both PI3K and mTOR pathways simultaneously may offer a potent strategy for immunosuppression.
• Combination therapies involving PI3K inhibitors, potentially isoform-selective, could represent novel immunosuppressive treatments.